Coughlin Timothy (CIK 0001376043)

Latest company ownership

Shares held
137,961
Last filed at
Feb 8, 2017
Confidence Score
50.0
2025Q4
Confidence Score History
2017Q1 2025Q4
ATYR - aTYR PHARMA INC
Role: Director
Shares held
56,000
Last filed at
Jun 3, 2024
Confidence Score
50.0
2025Q4
Confidence Score History
2024Q2 2025Q4
Shares held
40,000
Last filed at
Jun 11, 2024
Confidence Score
50.0
2025Q4
Confidence Score History
2016Q4 2025Q4
Shares held
10,000
Last filed at
Nov 4, 2025
Confidence Score
23.8
2025Q4
Confidence Score History
2025Q4 2025Q4

Recent buy/sell transactions

Exec date Filing date Company Role Signal Confidence Shares % of shares Under plan? Amount (USD)
Oct 31, 2025 Nov 4, 2025 Travere Therapeutics, Inc. Director Sell 12.5 -18,000 -24.49% ✓ $630.6K
May 30, 2024 Jun 3, 2024 aTYR PHARMA INC Director Buy 95.0 +50,000 833.33% ✗ $87.5K
Jun 3, 2022 Jun 6, 2022 FATE THERAPEUTICS INC Director Sell 26.3 -1,439 -2.44% ✗ $32.8K
Feb 6, 2017 Feb 8, 2017 NEUROCRINE BIOSCIENCES INC CFO Sell 51.3 -963 -0.69% ✓ $41.5K
Feb 3, 2017 Feb 6, 2017 NEUROCRINE BIOSCIENCES INC CFO Sell 45.0 -1,500 -1.09% ✓ $63.8K
Jan 17, 2017 Jan 18, 2017 NEUROCRINE BIOSCIENCES INC CFO Sell 45.0 -1,750 -1.28% ✓ $71.1K
Jan 10, 2017 Jan 12, 2017 NEUROCRINE BIOSCIENCES INC CFO Sell 45.0 -1,750 -1.30% ✓ $75.9K
Nov 23, 2016 Nov 28, 2016 FATE THERAPEUTICS INC Director Buy 95.0 +56,390 100.00% ✗ $150K